Date Published 
February 2014

Page Count 
122

Additional Info 
Single-site, country, and global licenses are multi-user, searchable, and cut-and-paste ready PDFs delivered by e-mail.

 

For Corporate Subscriptions, Multi-Reports Orders, Discounts or Order Questions.  

Contact:
Kerri Kelley
Customer Service
781-972-1347 


IPR Bundle

Molecular Diagnostic Market and Testing - Table of Contents

Executive Summary

PART I: Introduction and Market Background

CHAPTER 1: The Focus of This Report

CHAPTER 2: Market Trends and Adaptability

  • Lung cancer diagnostics market growth
  • Breast cancer diagnostics market growth
  • Thyroid cancer diagnostics market growth
  • Blood cancer diagnostics market growth
  • Prenatal diagnostics market growth

PART II: Cancer Diagnostics

CHAPTER 3: Lung Cancer

  • Types of lung cancer
  • Risk factors
  • Incidence
  • Symptoms and early detection
  • Targeted therapies

CHAPTER 4: Breast Cancer

  • Types of breast cancer
  • Risk factors
  • Incidence
  • Symptoms and early detection
  • Treatments for breast cancer

CHAPTER 5: GeneCentric

  • Company background
  • Lung Subtype Platform (LSP)
  • Hypoxia Signature Platform
  • GeneCentric outlook
  • Interview with Myla Lai-Goldman
    • Company background
    • Platforms
    • Future outlook

CHAPTER 6: Thyroid Cancer

  • Types
  • Risk
  • Symptoms and early detection
  • Therapeutic options

CHAPTER 7: Veracyte

  • Company background
  • Afirma Thyroid FNA Analysis
  • Validation
  • Competitive advantage
  • Future growth plans
  • Interview with Bonnie Anderson
    • Company background
    • Afirma Thyroid FNA Analysis
    • Competitive advantage
    • Challenges encountered
    • Future improvements

CHAPTER 8: Blood-Based Cancers

  • Leukemia
    • Types
    • Risk factors, symptoms and early detection
    • Therapeutic options
  • Lymphoma
    • Types
      • Classic Hodgkin disease
        • Nodular lymphocyte predominant Hodgkin disease
      • Non-Hodgkin lymphoma
    • Risk factors
    • Symptoms and therapeutic options

CHAPTER 9: Adaptive Biotechnologies Corporation

  • Company background
  • ClonoSEQ
  • Validation
  • Areas of improvement
  • Competitive advantage
  • Future endeavors
  • Interview with Chad Robins
    • Company background
    • ClonoSEQ
    • Areas of improvement
    • Challenges encountered
    • Competitive advantage
    • Future endeavors

PART III: Genetic Information and Prenatal Diagnostics

CHAPTER 10: Genetic Information and Prenatal Testing

  • Genetic information
  • Prenatal testing
    • Sequence-based cell-free DNA testing
    • Fetal cell isolation

CHAPTER 11: GenePeeks

  • Company background
  • Patented technology
  • How does the process work?
  • Validation
  • Accuracy and sensitivity
  • Areas of improvement
  • Competitive advantage
  • Future applications
  • Interview with Anne Morriss
    • Company background
    • Patented technology
    • Competitive advantage
    • Areas of improvement and future outlook

CHAPTER 12: Verinata Health

  • Company background
  • The verifi® prenatal test
  • Clinical validation and reimbursement
  • Customer feedback

CHAPTER 13: Testing Specifications

PART IV: Survey Demographics

CHAPTER 14: Survey Results

  • Survey demographics
  • Areas of study
  • Rising technologies
  • Challenges encountered

PART V: Company Directory

References

About Cambridge Healthtech Institute